AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
https://www.zacks.com/stock/news/2295441/abbvie-abbv-gets-chmp-nod-for-lymphoma-drug-s-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2295441
Jul 01, 2024 - AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
0
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
https://www.zacks.com/stock/news/2295379/merck-mrk-gets-chmp-nod-for-pah-drug-winrevair-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2295379
Jul 01, 2024 - Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
0
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
https://www.zacks.com/stock/news/2294903/pharma-stock-roundup-fda-s-crl-to-mrk-abbv-phase-iii-study-failures-for-nvo-azn?cid=CS-ZC-FT-analyst_blog|stock_roundup-2294903
Jun 28, 2024 - FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
0
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
https://www.zacks.com/stock/news/2294389/merck-s-mrk-lung-cancer-candidate-faces-fda-rejection?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2294389
Jun 27, 2024 - The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
0
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2293176/abbvie-abbv-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2293176
Jun 25, 2024 - AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.
0
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
https://www.zacks.com/stock/news/2291505/pharma-stock-roundup-fda-nod-to-mrk-s-new-jab-expanded-use-of-abbv-azn-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2291505
Jun 21, 2024 - FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
0
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
https://www.zacks.com/stock/news/2291318/j-j-jnj-seeks-expanded-use-of-tremfya-for-crohn-s-disease?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2291318
Jun 21, 2024 - J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
0
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
https://www.fool.com/investing/2024/06/20/10-stocks-to-build-a-dividend-portfolio-that-will/?source=iedfolrf0000001
Jun 20, 2024 - The power of compounding can build huge amounts of passive income.
0
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
https://www.zacks.com/stock/news/2290520/why-abbvie-abbv-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2290520
Jun 19, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
0
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
https://www.zacks.com/stock/news/2290253/abbvie-s-abbv-skyrizi-gets-fda-nod-for-ulcerative-colitis?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290253
Jun 19, 2024 - AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.
0